Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.

Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
复制标题

DOI:
10.3390/ijms22052283
复制
发表时间:
2021-02-25
影响因子:
5.6
通讯作者:
Lane HY
Lane HY
中科院分区:
生物学2区
文献类型:
--
作者:
Cheng YJ;Lin CH;Lane HY

文献摘要

参考文献

被引文献

相似文献

阿尔茨海默病(Alzheimer's disease,AD)是一种进行性神经退行性疾病,是痴呆的最常见病因。AD病例的数量在全球范围内迅速增长。一些相关的病因学假说包括非典型淀粉样蛋白β(Aβ)沉积、神经元内tau蛋白的神经元缠结、神经传递紊乱、炎症和氧化应激。在AD进展过程中,神经传递的异常导致认知功能下降-AD的主要症状。本文综述了与AD相关的胆碱能、肾上腺素能和多巴胺能神经传递系统的异常及其相互作用。我们还讨论了N-甲基-D-天冬氨酸受体(NMDAR)功能障碍在AD相关认知功能障碍中的关键作用。此外,我们总结了最近的研究结果表明,通过改变NMDARs增加海马能神经传递显示出治疗轻度认知障碍或早期AD的认知下降的潜力。未来的研究在AD治疗中的NMDA增强策略的长期有效性是必要的。
Alzheimer’s disease (AD), the most common cause of dementia, is a progressive neurodegenerative disease. The number of AD cases has been rapidly growing worldwide. Several the related etiological hypotheses include atypical amyloid β (Aβ) deposition, neurofibrillary tangles of tau proteins inside neurons, disturbed neurotransmission, inflammation, and oxidative stress. During AD progression, aberrations in neurotransmission cause cognitive decline—the main symptom of AD. Here, we review the aberrant neurotransmission systems, including cholinergic, adrenergic, and glutamatergic network, and the interactions among these systems as they pertain to AD. We also discuss the key role of N-methyl-d-aspartate receptor (NMDAR) dysfunction in AD-associated cognitive impairment. Furthermore, we summarize the results of recent studies indicating that increasing glutamatergic neurotransmission through the alteration of NMDARs shows potential for treating cognitive decline in mild cognitive impairment or early stage AD. Future studies on the long-term efficiency of NMDA-enhancing strategies in the treatment of AD are warranted.
DOI: 10.1016/0022-510x(83)90045-x
发表时间: 1983-01-01
影响因子: 4.4
作者:
CANDY, JM;PERRY, RH;TOMLINSON, BE
通讯作者: TOMLINSON, BE
DOI: 10.1007/bf02246146
发表时间: 1995-07-01
期刊: PSYCHOPHARMACOLOGY
影响因子: 3.4
作者:
CORBETT, R;CAMACHO, F;DUNN, RW
通讯作者: DUNN, RW
DOI: 10.1002/alz.12068
发表时间: 2020-03-01
影响因子: 14
作者:
通讯作者: --
DOI: 10.1016/0006-8993(88)90827-x
发表时间: 1988-06-28
期刊: BRAIN RESEARCH
影响因子: 2.9
作者:
ALLEN, SJ;DAWBARN, D;WILCOCK, GK
通讯作者: WILCOCK, GK
DOI: 10.2147/eb.s16998
发表时间: 2011-01-01
期刊: EYE AND BRAIN
影响因子: 4.4
作者:
Balaram, Pooja;Takahata, Toru;Kaas, Jon H.
通讯作者: Kaas, Jon H.